Stargardt Disease Clinical Trial
Official title:
ACDN-01-001: Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Subretinal ACDN-01 in Participants With ABCA4-related Retinopathy
This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.
This is an open-label, single ascending dose study of ACDN-01 in adult participants with ABCA4-related retinopathy. The study is designed to evaluate the safety, tolerability, and evidence of biological effect of SAD levels (low, medium, and high) of ACDN-01 when delivered subretinally. Participants will be followed on study for 2 years for the primary safety and preliminary efficacy endpoints, after which they will continue in the study in a 3-year long-term follow-up period, for a total study duration of 5 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01676766 -
Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease
|
N/A | |
| Enrolling by invitation |
NCT06048185 -
Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
|
||
| Recruiting |
NCT04545736 -
Oral Metformin for Treatment of ABCA4 Retinopathy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05674058 -
Function and Imaging Assessments for G1961E-associated Stargardt Disease
|
||
| Recruiting |
NCT06435000 -
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
|
||
| Completed |
NCT04909398 -
Pupil Dynamics and Color Vision for the Detection of Eye Diseases
|
N/A | |
| Completed |
NCT02255981 -
Efficacy of Acupuncture in Macular Diseases
|
N/A | |
| Completed |
NCT05266014 -
This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02435940 -
Inherited Retinal Degenerative Disease Registry
|
||
| Recruiting |
NCT06445322 -
Prescreening Study to Identify Potential Participants for ACDN-01 Clinical Trials
|
||
| Completed |
NCT05417126 -
Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease
|
Phase 2 | |
| Completed |
NCT03772665 -
Safety and Efficacy of Emixustat in Stargardt Disease
|
Phase 3 | |
| Terminated |
NCT02875704 -
Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy
|
||
| Completed |
NCT03033108 -
Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease
|
Phase 2 | |
| Recruiting |
NCT03011541 -
Stem Cell Ophthalmology Treatment Study II
|
N/A | |
| Completed |
NCT02410122 -
The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy
|
||
| Enrolling by invitation |
NCT04239625 -
Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)
|
Phase 2 | |
| Recruiting |
NCT05956626 -
Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02402660 -
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
|
Phase 2 | |
| Completed |
NCT01977846 -
A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
|